Summaries of peer-reviewed trials exploring cannabis in pain, sleep, and neurology.
Helius Therapeutics has today announced a supply agreement with the University of Auckland for a new Phase 2 trial into cannabis as a sleep aid for patients which chronic back pain.
Argent BioPharma (RGT), formerly MGC Pharmaceuticals, has sold the global commercialisation rights of its leading epilepsy drug, CannEpil, in order to clear a sizable chunk of its debt.
This week, what is perhaps the most consequential hearing in the history of the US, and indeed the global cannabis industry, is taking place in Arlington, Virginia.
Few conditions in the field of medical cannabis are backed by such adamant patient conviction, but as little clinical data as Attention Deficit Hyperactivity Disorder (ADHD).
A major new systematic review has concluded that the available evidence rarely justifies the routine prescribing of cannabinoids for mental health conditions and substance use disorders.
US cannabis rescheduling is unlikely to trigger a land grab.
In our latest Beyond the Abstract, we dive into cannabis use and its impact on mental health, a controversial and understudied field, but one of vital importance for both patient safety and potential relief for millions.
Ananda Pharma has cleared the final regulatory hurdle needed to begin its ENDOCAN Phase 2 clinical trial, receiving approval from the MHRA and NHS Health Research Authority to commence dosing of its proprietary MRX1 CBD oral solution in women with endometriosis-associated pain.
Across global cannabis markets, the average levels of THC content are continuing a sustained, exponential and well-documented rise.
